Show simple item record

dc.contributor.authorNyberg, Tommy
dc.contributor.authorTischkowitz, Marc
dc.contributor.authorAntoniou, Antonis C
dc.date.accessioned2022-04-04T15:00:28Z
dc.date.available2022-04-04T15:00:28Z
dc.date.issued2022-04
dc.date.submitted2021-08-25
dc.identifier.issn0007-0920
dc.identifier.others41416-021-01675-5
dc.identifier.other1675
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/335740
dc.description.abstractBACKGROUND: BRCA1 and BRCA2 pathogenic variants (PVs) are associated with prostate cancer (PCa) risk, but a wide range of relative risks (RRs) has been reported. METHODS: We systematically searched PubMed, Embase, MEDLINE and Cochrane Library in June 2021 for studies that estimated PCa RRs for male BRCA1/2 carriers, with no time or language restrictions. The literature search identified 27 studies (BRCA1: n = 20, BRCA2: n = 21). RESULTS: The heterogeneity between the published estimates was high (BRCA1: I2 = 30%, BRCA2: I2 = 83%); this could partly be explained by selection for age, family history or aggressive disease, and study-level differences in ethnicity composition, use of historical controls, and location of PVs within BRCA2. The pooled RRs were 2.08 (95% CI 1.38-3.12) for Ashkenazi Jewish BRCA2 carriers, 4.35 (95% CI 3.50-5.41) for non-Ashkenazi European ancestry BRCA2 carriers, and 1.18 (95% CI 0.95-1.47) for BRCA1 carriers. At ages <65 years, the RRs were 7.14 (95% CI 5.33-9.56) for non-Ashkenazi European ancestry BRCA2 and 1.78 (95% CI 1.09-2.91) for BRCA1 carriers. CONCLUSIONS: These PCa risk estimates will assist in guiding clinical management. The study-level subgroup analyses indicate that risks may be modified by age and ethnicity, and for BRCA2 carriers by PV location within the gene, which may guide future risk-estimation studies.
dc.description.sponsorshipCancer Research UK [grants C12292/A20861, C12292/A22820 and PPRPGM-Nov20\100002]; supported by the National Institute for Health Research Cambridge Biomedical Research Centre.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectArticle
dc.subject/631/67/2324
dc.subject/631/67/68/2486
dc.subject/631/67/589/466
dc.subject/692/499
dc.subjectarticle
dc.titleBRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis.
dc.typeArticle
dc.date.updated2022-04-04T15:00:27Z
prism.endingPage1081
prism.issueIdentifier7
prism.publicationNameBr J Cancer
prism.startingPage1067
prism.volume126
dc.identifier.doi10.17863/CAM.83177
dcterms.dateAccepted2021-12-10
rioxxterms.versionofrecord10.1038/s41416-021-01675-5
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidNyberg, Tommy [0000-0002-9436-0626]
dc.contributor.orcidTischkowitz, Marc [0000-0002-7880-0628]
dc.contributor.orcidAntoniou, Antonis C [0000-0001-9223-3116]
dc.identifier.eissn1532-1827
pubs.funder-project-idCancer Research UK (S_3380)
pubs.funder-project-idCancer Research UK (C12292/A22820)
pubs.funder-project-idCancer Research UK (20861)
cam.issuedOnline2021-12-28


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record